PELNSEPiramal Enterprises Limited· PharmaceuticalsMediumNeutral
Announced Tue, 6 May · 17:24 IST

"Piramal Enterprises Limited has informed the Exchange regarding press release dated 6th May, 2025".

Mgmt Guided Margin ImprovementAnalyst Day Multiyear TargetsInvestor Communications View source PDF
Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Piramal Enterprises reported consolidated PAT of INR 485 Cr for FY25, a turnaround from a loss of INR 1,684 Cr in FY24, with Q4 FY25 PAT at INR 102 Cr. Total AUM grew 17% YoY to INR 80,689 Cr, driven by retail (up 35% YoY to INR 64,652 Cr, 80% of AUM) and Wholesale 2.0 (up 44% YoY to INR 9,117 Cr). Legacy AUM shrank 53% YoY to INR 6,920 Cr (9% of total). The company met all FY25 stated targets. Key updates include RBI approval for the PEL-Piramal Finance merger (expected by Sep 2025), USD 815 mn raised from global markets in FY25, capital adequacy at 23.6%, GNPA at 2.8%, and opex-to-AUM improving 220 bps over 8 quarters to 4.3%. Management guided FY26 for ~25% YoY AUM growth and consolidated PAT of INR 1,300–1,500 Cr.

Likely market impact

The strong AUM growth, return to profitability, met FY25 targets, RBI-approved merger, and clear FY26 PAT guidance (nearly 3x growth) are positive signals. Shareholders can expect a simplified group structure post-merger and sharper profit growth, though borrowings rose to INR 65,484 Cr and credit costs ticked up slightly in Q4.